Cargando…

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions

Parkinson’s disease (PD) is the second-most common neurodegenerative disorder with a long-term 60% cumulative prevalence of PD psychosis. Medical treatment is limited to few atypical antipsychotic drugs with low affinity to dopamine D2 receptors. In 2016, pimavanserin, a selective 5-HT2A inverse ago...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heim, Beatrice, Peball, Marina, Krismer, Florian, Djamshidian, Atbin, Seppi, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239266/ https://www.ncbi.nlm.nih.gov/pubmed/37274140 http://dx.doi.org/10.2147/NDT.S371641

Ejemplares similares

Differentiating Parkinson’s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis
por: Heim, Beatrice, et al.
Publicado: (2022)

Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease
por: Valent, Dora, et al.
Publicado: (2023)

α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—A Systematic Review and Meta‐Analysis
por: Grossauer, Anna, et al.
Publicado: (2023)

Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson’s Disease
por: Peball, Marina, et al.
Publicado: (2023)

Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study
por: Peball, Marina, et al.
Publicado: (2022)

Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
por: Ellmerer, Philipp, et al.
Publicado: (2022)

Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis
por: Peball, Marina, et al.
Publicado: (2022)

Anti‐IgLON5 Disease with Isolated Hemichorea: A Case Report and Review of the Literature
por: Grossauer, Anna, et al.
Publicado: (2022)

Time will tell: Decision making in premanifest and manifest Huntington’s disease
por: Heim, Beatrice, et al.
Publicado: (2020)

Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
por: Peball, Marina, et al.
Publicado: (2020)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
por: Carbone, Federico, et al.
Publicado: (2019)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
por: Peball, Marina, et al.
Publicado: (2019)

Magnetic resonance imaging for the diagnosis of Parkinson’s disease
por: Heim, Beatrice, et al.
Publicado: (2017)

Different assessment tools to detect sarcopenia in patients with Parkinson's disease
por: Valent, Dora, et al.
Publicado: (2022)

Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis
por: Heim, Beatrice, et al.
Publicado: (2021)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders
por: Heim, Beatrice, et al.
Publicado: (2021)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Augmentation in restless legs syndrome: an eye tracking study on emotion processing
por: Ellmerer, Philipp, et al.
Publicado: (2020)

Factors associated with augmentation in patients with restless legs syndrome
por: Heim, Beatrice, et al.
Publicado: (2021)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

Cardiac sympathetic innervation in Parkinson’s disease versus multiple system atrophy
por: Eckhardt, Christine, et al.
Publicado: (2022)

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
por: Poewe, Werner, et al.
Publicado: (2021)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f7k0noqr1a5k1fetq79ib0559a